Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Background: Down syndrome (DS) individuals, by the age of 40s, are at increased risk to develop Alzheimer-like dementia, with deposition in brain of senile plaques and neurofibrillary tangles. Our laboratory recently demonstrated the disturbance of PI3K/AKT/mTOR axis in DS brain, prior and after the development of Alzheimer Disease (AD). The aberrant modulation of the mTOR signalling in DS and AD age-related cognitive decline affects crucial neuronal pathways, including insulin signaling and autophagy, involved in pathology onset and progression. Within this context, the therapeutic use of mTOR-inhibitors may prevent/attenuate the neurodegenerative phenomena. By our work we aimed to rescue mTOR signalling in DS mice by a novel rapamycin intranasal administration protocol (InRapa) that maximizes brain delivery and reduce systemic side effects. Methods: Ts65Dn mice were administered with InRapa for 12 weeks, starting at 6 months of age demonstrating, at the end of the treatment by radial arms maze and novel object recognition testing, rescued cognition. Results: The analysis of mTOR signalling, after InRapa, demonstrated in Ts65Dn mice hippocampus the inhibition of mTOR (reduced to physiological levels), which led, through the rescue of autophagy and insulin signalling, to reduced APP levels, APP processing and APP metabolites production, as well as, to reduced tau hyperphosphorylation. In addition, a reduction of oxidative stress markers was also observed. Discussion: These findings demonstrate that chronic InRapa administration is able to exert a neuroprotective effect on Ts65Dn hippocampus by reducing AD pathological hallmarks and by restoring protein homeostasis, thus ultimately resulting in improved cognition. Results are discussed in term of a potential novel targeted therapeutic approach to reduce cognitive decline and AD-like neuropathology in DS individuals

Ruolo della colon-TC nel paziente anziano con colonscopia controindicata o incompleta

Scopo: Valutare accuratezza, efficacia diagnostica e sicurezza della colon-TC (CTC) in pazienti anziani con sospetta patologia non candidabili alla colonscopia o nei quali quest\u2019ultima fosse risultata incompleta e non dirimente per la diagnosi. Materiali e metodi: Sono state eseguite 83 CTC in pazienti con et\ue0 >= 75 anni (media 86 \ub1 5,52; range 75-97) per completamento diagnostico in caso di colonscopia controindicata o incompleta, come da linee guida ESGE/ESGAR 2015. Gli esami si sono svolti previa preparazione intestinale, fecaltagging, insufflazione rettale di CO2 e iniezione endovenosa di spasmolitico, salvo controindicazioni. Sono state effettuate scansioni dirette a paziente prono e supino, ricostruzioni multiplanari e navigazione 3D. Ogni studio \ue8 stato esaminato da 2 radiologi. Risultati: La preparazione intestinale \ue8 stata valutata soddisfacente nel 80,7% dei casi. La quantit\ue0 media di CO2 insufflata \ue8 stata di 3,6 litri. La valutazione dei segmenti colici dopo distensione, compresa la navigazione 3D, \ue8 stata completa nel 91,6% dei pazienti, con un picco del 96,1% nei 55 pazienti di et\ue0 compresa tra 75 e 85 anni. 62 esami (74,7%) sono risultati positivi: 19 per polipi di dimensioni > 6 mm (5 sessili e 14 peduncolati), 12 per ispessimenti parietali di tipo neoplastico, 45 per patologia diverticolare; in 14 casi si \ue8 avuta la concomitante presenza di pi\uf9 reperti. Nessuna complicanza procedurale. Conclusioni: La CTC, nei pazienti ultrasettantacinquenni con sufficienti preparazione intestinale ed insufflazione rettale di CO2, completa in gran parte dei casi la diagnosi di una sospetta patologia colica in modo sicuro, relativamente poco invasivo e ben tollerato, consentendo una pronta prosecuzione delle cure

The Performance and Potentiality of Monoecious Hemp (Cannabis sativa L.) Cultivars as a Multipurpose Crop

Given the growing interest in multipurpose hemp crop, eight monoecious cultivars were compared in a two-year trial for quantitative and qualitative yield in a Mediterranean environment characterized by a temperate and humid climate with hot summers. All hemp cultivars were evaluated for yield potential of (i) seed plus stem at seed maturity, and (ii) essential oil yield from inflorescences harvested at full flowering. The second goal was set to test the ability of cultivars to supply new seeds after the removal of inflorescence at full flowering. Among the cultivars, Fedora obtained the best results for seed (0.79 and 0.52 t ha1) and vegetable oil yield (0.17 and 0.09 t ha1) normally and with inflorescence removed plants, respectively. Futura, conversely, showed the best results for inflorescence (3.0 t ha1), essential oil (9 L ha1), and stem yield at seed maturity (8.34 t ha1), as means across the two years. The cultivars studied generally reached the grain-filling stage during a period that was drier and warmer than the average of the same multi-year period, and this negatively affected seed quality. The oil fatty acid composition was mainly composed of polyunsaturated fatty acids (75% on average) and not affected by the cultivar. In conclusion, although the hemp grower should always clearly know the main production objective of the crop, the monoecious cultivars available today allow a multipurpose use of hemp crop, improving the sustainability of the cultivation activity

Relationship between gastric pouch and GERD after laparoscopic sleeve gastrectomy

open9noAims and objectives Laparoscopic Sleeve Gastrectomy (LSG) is considered safe and effective even as conversion procedure after primary bariatric operations. The correlation between gastric pouch volumes and gastro-esophageal reflux disease's (GERD) symptoms (heartburn, reflux, regurgitation) remains unclear (1, 2). With this study we want to assess a correlation between the gastric remnant size and GERD.openPomerri, F.; Romanucci, G.; Barbiero, G.; Zuliani, M.; Ortu, V.; Miotto, D.; Albanese, A.; Prevedello, L.; Foletto, M.Pomerri, Fabio; Romanucci, G.; Barbiero, G.; Zuliani, M.; Ortu, V.; Miotto, Diego; Albanese, A.; Prevedello, L.; Foletto, M

Intranasal Rapamycin Ameliorates Alzheimer-Like Cognitive Decline in a Mouse Model of Down Syndrome

Background: Down syndrome (DS) individuals, by the age of 40s, are at increased risk to develop Alzheimer-like dementia, with deposition in brain of senile plaques and neurofibrillary tangles. Our laboratory recently demonstrated the disturbance of PI3K/AKT/mTOR axis in DS brain, prior and after the development of Alzheimer Disease (AD). The aberrant modulation of the mTOR signalling in DS and AD age-related cognitive decline affects crucial neuronal pathways, including insulin signaling and autophagy, involved in pathology onset and progression. Within this context, the therapeutic use of mTOR-inhibitors may prevent/attenuate the neurodegenerative phenomena. By our work we aimed to rescue mTOR signalling in DS mice by a novel rapamycin intranasal administration protocol (InRapa) that maximizes brain delivery and reduce systemic side effects. Methods: Ts65Dn mice were administered with InRapa for 12 weeks, starting at 6 months of age demonstrating, at the end of the treatment by radial arms maze and novel object recognition testing, rescued cognition. Results: The analysis of mTOR signalling, after InRapa, demonstrated in Ts65Dn mice hippocampus the inhibition of mTOR (reduced to physiological levels), which led, through the rescue of autophagy and insulin signalling, to reduced APP levels, APP processing and APP metabolites production, as well as, to reduced tau hyperphosphorylation. In addition, a reduction of oxidative stress markers was also observed. Discussion: These findings demonstrate that chronic InRapa administration is able to exert a neuroprotective effect on Ts65Dn hippocampus by reducing AD pathological hallmarks and by restoring protein homeostasis, thus ultimately resulting in improved cognition. Results are discussed in term of a potential novel targeted therapeutic approach to reduce cognitive decline and AD-like neuropathology in DS individuals

Rapporto 2007 su consumo e dipendenze da sostanze in Emilia-Romagna.

Report on the state of legal and illegal substances use in the territory of Emilia-Romagna Region.Il report analizza il fenomeno delle dipendenze nel territorio della Regione Emilia-Romagna. La descrizione del fenomeno si sviluppa intorno all\u27analisi degli indicatori individuati dall\u27Osservatorio Europeo delle Dipendenze di Lisbona (OEDT): 1-uso di sostanze nella popolazione generale (questo indicatore va a rilevare i comportamenti nei confronti di alcol e sostanze psicoattive da parte della popolazione generale); 2-prevalenza d\u27uso problematico delle sostanze psicoattive; 3-domanda di trattamento degli utilizzatori di sostanze; 4-mortalit? degli utilizzatori di sostanze; 5-malattie infettive. Altri due importanti indicatori che si stanno sviluppando, e che vengono qui illustrati, sono l\u27analisi delle Schede di Dimissione Ospedaliera (SDO) e gli indicatori relativi alle conseguenza sociali dell\u27uso di droghe (criminalit? droga correlata). Inoltre sono state applicate diverse metodologie standard di stima sia per quantificare la quota parte sconosciuta di utilizzatori di sostanze che non afferiscono ai servizi, sia per identificarne alcune caratteristiche

"Delirium Day": A nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool

Background: To date, delirium prevalence in adult acute hospital populations has been estimated generally from pooled findings of single-center studies and/or among specific patient populations. Furthermore, the number of participants in these studies has not exceeded a few hundred. To overcome these limitations, we have determined, in a multicenter study, the prevalence of delirium over a single day among a large population of patients admitted to acute and rehabilitation hospital wards in Italy. Methods: This is a point prevalence study (called "Delirium Day") including 1867 older patients (aged 65 years or more) across 108 acute and 12 rehabilitation wards in Italian hospitals. Delirium was assessed on the same day in all patients using the 4AT, a validated and briefly administered tool which does not require training. We also collected data regarding motoric subtypes of delirium, functional and nutritional status, dementia, comorbidity, medications, feeding tubes, peripheral venous and urinary catheters, and physical restraints. Results: The mean sample age was 82.0 ± 7.5 years (58 % female). Overall, 429 patients (22.9 %) had delirium. Hypoactive was the commonest subtype (132/344 patients, 38.5 %), followed by mixed, hyperactive, and nonmotoric delirium. The prevalence was highest in Neurology (28.5 %) and Geriatrics (24.7 %), lowest in Rehabilitation (14.0 %), and intermediate in Orthopedic (20.6 %) and Internal Medicine wards (21.4 %). In a multivariable logistic regression, age (odds ratio [OR] 1.03, 95 % confidence interval [CI] 1.01-1.05), Activities of Daily Living dependence (OR 1.19, 95 % CI 1.12-1.27), dementia (OR 3.25, 95 % CI 2.41-4.38), malnutrition (OR 2.01, 95 % CI 1.29-3.14), and use of antipsychotics (OR 2.03, 95 % CI 1.45-2.82), feeding tubes (OR 2.51, 95 % CI 1.11-5.66), peripheral venous catheters (OR 1.41, 95 % CI 1.06-1.87), urinary catheters (OR 1.73, 95 % CI 1.30-2.29), and physical restraints (OR 1.84, 95 % CI 1.40-2.40) were associated with delirium. Admission to Neurology wards was also associated with delirium (OR 2.00, 95 % CI 1.29-3.14), while admission to other settings was not. Conclusions: Delirium occurred in more than one out of five patients in acute and rehabilitation hospital wards. Prevalence was highest in Neurology and lowest in Rehabilitation divisions. The "Delirium Day" project might become a useful method to assess delirium across hospital settings and a benchmarking platform for future surveys